Allena Pharmaceuticals, Inc. Non Cash Items (Other)

Non Cash Items (Other) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non Cash Items (Other) growth rates and interactive chart.


Highlights and Quick Summary

  • Non Cash Items (Other) for the quarter ending March 31, 2022 was $755 Thousand (a -17.31% decrease compared to previous quarter)
  • Year-over-year quarterly Non Cash Items (Other) decreased by -30.41%
  • Annual Non Cash Items (Other) for 2021 was $4.11 Million (a -12.27% decrease from previous year)
  • Annual Non Cash Items (Other) for 2020 was $4.68 Million (a 34.34% increase from previous year)
  • Annual Non Cash Items (Other) for 2019 was $3.48 Million (a 23.2% increase from previous year)
  • Twelve month Non Cash Items (Other) ending March 31, 2022 was $3.9 Million (a -4.97% decrease compared to previous quarter)
  • Twelve month trailing Non Cash Items (Other) decreased by -11.7% year-over-year
Trailing Non Cash Items (Other) for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$3.9 Million $4.11 Million $4.31 Million $4.42 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non Cash Items (Other) of Allena Pharmaceuticals, Inc.

Most recent Non Cash Items (Other)of ALNA including historical data for past 10 years.

Interactive Chart of Non Cash Items (Other) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Non Cash Items (Other) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.76
2021 $0.91 $1.15 $1.09 $0.96 $4.11
2020 $1.12 $1.25 $1.14 $1.17 $4.68
2019 $0.9 $0.94 $0.9 $0.76 $3.48
2018 $0.54 $0.6 $1.21 $0.48 $2.83
2017 $0.37 $0.36 $0.21 $0.18 $1.13
2016 $0.25 $0.59
2015 $0.42

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.